Tharimmune (THAR)

• Market cap: $84.1M
• 1 day: 0.42%
• 5 days: -3.23%
• 1 month: -13.67%
• 3 months: -18.37%
• 6 months: 81.82%
• Year to date: 17.07%
• 1 year: 10.6%
• 5 years: -99.82%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3